Veltassa

Quick links to important sections

Veltassa

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veltassa

Veltassa: Identity and Pharmacological Class

Property Description
Active ingredient Patiromer (as patiromer sorbitex calcium)
Form Powder for oral suspension (in sachets)
Pharmacological class Potassium binder / Cation exchange polymer
Common use Management of elevated blood potassium levels (hyperkalemia)
Origin Synthetic, non-absorbed spherical polymer

Veltassa is a prescription-only medication indicated for managing hyperkalemia, a condition characterized by high levels of potassium in the blood. The active ingredient is patiromer (specifically patiromer sorbitex calcium), a potassium binder belonging to the pharmacological class of cation exchange polymers. This classification confirms that the medicine's primary function is to chemically capture potassium.

This substance represents a modern approach in its class. The polymer is not systemically absorbed, a key feature that confines its therapeutic action entirely to the gastrointestinal tract. The polymer is supplied as a powder for oral suspension in single-use sachets suitable for oral administration after being mixed with liquid or soft food.

Composition and Therapeutic Purpose

Patiromer's composition involves the active ingredient complexed with calcium-sorbitol, which serves as the counterion. This is a distinguishing feature, as the polymer selectively exchanges its calcium ions for potassium ions within the colon lumen. The drug's non-absorbed characteristic ensures its action is localized, directly supporting its general therapeutic purpose: to help lower and maintain balanced serum potassium levels.

The mechanism achieves this benefit by increasing fecal potassium excretion. By capturing and binding potassium ions in the intestine, Patiromer reduces the concentration of free potassium available for reabsorption into the body, which is essential for the effective management of hyperkalemia. Within its therapeutic application, the medication acts to reduce serum potassium concentrations.

Regulatory References

  1. EMA Veltassa EPAR page

What side effects are possible with Veltassa?

Possible Side Effects and Safety Information

The safety profile for patiromer (Veltassa) is predominantly characterized by adverse reactions localized to the gastrointestinal tract and disturbances in the Metabolism and Nutrition system-organ class, as documented by regulatory agencies like the FDA and EMA. The classification of these effects is based on frequency observed during clinical trials.

Frequency-Classified Adverse Reactions

The most frequently reported effects are related to the drug's action as a non-absorbed polymer in the colon.

Classification Adverse Reaction System-Organ Class
Very Common (ge 1/10) Constipation, Hypomagnesemia Gastrointestinal; Metabolism and Nutrition
Common (ge 1/100 to <1/10) Diarrhea, Nausea, Abdominal discomfort, Flatulence Gastrointestinal

Hypomagnesemia (low blood magnesium) is a key effect classified as Very Common. Hypersensitivity reactions (e.g., edema of the lips) have been reported as Uncommon.

General Safety Constraints

The medicine is explicitly not intended for use as emergency treatment for life-threatening hyperkalemia due to its delayed onset of action. Furthermore, regulatory documents advise against its use in patients with severe gastrointestinal disorders, including severe constipation, bowel obstruction or impaction, or conditions involving abnormal post-operative bowel motility. The polymer's binding potential requires that the administration of other oral medications be separated in time to prevent reduced absorption.

Clinical evidence indicates that the safety profile observed in older adults and adolescents (12 to 17 years) is generally similar to that reported in the general adult population. The most common gastrointestinal side effect, constipation, was observed in trials to generally resolve during the course of treatment.

Overdose and Emergency Response

The regulatory information on Veltassa (Patiromer) overdose establishes that the main outcome of taking excessive amounts is the risk of hypokalemia, defined as an abnormally low concentration of potassium in the blood. This condition is the sole documented clinical manifestation of overdose stated in the official prescribing information. Since hypokalemia is the primary concern, the required management protocol focuses on monitoring serum potassium levels closely and implementing appropriate supportive measures to restore potassium to a safe range if needed. Management is considered symptomatic because there is no specific antidote documented in the official regulatory labels for Veltassa overdose.

Patients or caregivers are instructed to seek immediate medical attention or contact a Poison Help line immediately following a suspected overdose. Urgent medical assistance, such as contacting emergency services, must be sought when the individual exhibits severe symptoms, including collapsing, experiencing a seizure, having trouble breathing, or being unable to be awakened. The regulatory labels also specify a key constraint for emergency use: Veltassa is not intended for the emergency treatment of life-threatening acute hyperkalemia due to its slow therapeutic onset. Lastly, clinical studies regarding the safety and effects of doses exceeding 50.4 grams per day have not been performed, establishing a limit on the exposure levels assessed by regulators.

Therapeutic Uses of Veltassa

Long-Term Correction of High Blood Potassium (Hyperkalemia)

Veltassa is relevant for easing symptoms related to systemic imbalance, specifically hyperkalemia, a condition where potassium levels in the blood are elevated. Because high potassium can be associated with serious heart problems, Veltassa is commonly used to help with this condition in relevant adult and pediatric patient groups. This medication may assist with managing symptoms related to systemic imbalance by supporting potassium levels over an extended period. The primary benefit is providing support for balancing systemic potassium levels, which contributes to easing the overall symptom load associated with heightened physiological activity. Veltassa is relevant in contexts involving heightened systemic burden.


Managing Risk to Enable Essential Heart and Kidney Therapy

Veltassa is considered relevant for managing hyperkalemia in conditions involving episodic or fluctuating manifestations, specifically those with Chronic Kidney Disease (CKD) and/or Heart Failure (HF). This is relevant when supportive symptom management is appropriate due to the use of certain protective medications. Veltassa plays a role in managing this condition, which may assist with supporting patients to continue with therapeutic regimens that involve these protective medications. The use of this therapy supports patients during episodes of heightened discomfort.

“This medication is commonly used to help manage systemic potassium levels and assists with maintaining functional stability.”

Quick Fact: Relief for Systemic Imbalance Veltassa is primarily used in the management of hyperkalemia across relevant adult and pediatric patient groups with Chronic Kidney Disease and Heart Failure.

Eligibility and Restrictions for Use

Veltassa (patiromer) is a prescription medicine indicated for the treatment of high potassium levels (hyperkalemia) in certain populations. The decision to use this medicine is strictly governed by regulatory guidelines regarding eligibility and contraindications.

Age-Related Eligibility

  • Allowed: Adults and pediatric patients ages 12 years and older.
  • Use Not Established: Safety and effectiveness have not been established in children under 12 years of age.

Contraindications (Must Not Use)

Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components. Additionally, the European regulatory label states that use is contraindicated in patients with hereditary fructose intolerance due to the sorbitol content.

Restrictions and Special Considerations

  • Emergency Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
  • Gastrointestinal Motility: Avoid use in patients with severe constipation, bowel obstruction, or impaction, including abnormal post-operative bowel motility disorders, as this may worsen the condition.
  • Pregnancy and Lactation: Maternal use during pregnancy and lactation is not expected to result in risk to the fetus or infant, as the medicine is not absorbed systemically by the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Patiromer (Veltassa) is a non-absorbed polymer, and its official interaction profile is characterized by non-systemic effects. It does not interact with systemic metabolic enzymes, such as the CYP450 system, or affect drug transporters; therefore, systemic drug–drug interactions are not a clinical concern.

Pharmacokinetic and Pharmacodynamic Interactions

  • Physical Binding: The primary pharmacokinetic interaction is the ability of patiromer to bind certain orally administered medications in the gastrointestinal tract, which can lead to reduced absorption and lower systemic exposure of the affected drugs.
  • Mineral Binding: A documented pharmacodynamic interaction is the binding of magnesium in the colon, which carries the potential risk of reduced serum magnesium levels (hypomagnesemia).

Mandatory Administration Timing Rule

To mitigate the risk of reduced exposure due to physical binding, regulatory authorities require a mandatory separation rule for nearly all oral medicinal products. All other oral medicines must be administered at least three hours before or three hours after patiromer.

Specific Substance Restrictions

Regulatory documentation includes procedural and substance-specific constraints. The powder must not be heated or added to hot liquids. There are no formally documented contraindications based on a drug–drug interaction.

Mechanism of Action

Veltassa’s mechanism is entirely confined to the gastrointestinal tract and involves the chemical process of cation exchange. The active component, patiromer, is a synthetic, non-absorbed polymer that functions as a physical binding matrix.


Cation Exchange and Potassium Sequestration

The primary mechanistic domain is the non-systemic chemical binding of the target ion. Patiromer enters the colon lumen and selectively releases its counter-ion ( Ca^2+) to capture and bind potassium ions ( K^+). This process, which occurs across the distal GI tract, results in the sequestration of K^+ within a large, insoluble polymer complex, limiting its potential for reabsorption into the bloodstream.


Increased Fecal Excretion and Systemic Balance

The binding and sequestration of potassium facilitates its physical removal from the body. The patiromer- K^+ complex is non-absorbable and is consequently eliminated via fecal excretion, directly increasing the net amount of potassium removed from the system. This functional consequence of the mechanism affects the body’s overall net potassium balance, leading to a reduction of the concentration of potassium in the blood.

Dosage and Administration Information

How to Use Veltassa: Official Administration Guidelines

Veltassa (patiromer) is prescribed for the ongoing management of hyperkalemia. The drug is administered strictly according to prescribed instructions, focusing on proper route, preparation, dosing, and schedule, with no intent for emergency use.


Administration Scope and Dosing

Veltassa is for oral use only as a powder for suspension. The powder must be prepared immediately before administration and never consumed in its dry form.

Feature Instruction
Standard Adult Dose Starting Dose: 8.4 grams once daily. Maximum Dose: 25.2 grams once daily.
Dose Adjustment Can be adjusted by 8.4 grams at 1-week or longer intervals based on serum potassium levels.
Frequency Taken once daily.
Pediatric Use (12-17 years) Starting Dose: 4 grams once daily. Safety is not established for children under 12.

Preparation and Procedural Conditions

Correct preparation is essential for proper use. The powder can be taken with or without food.

  • Preparation: Mix the powder with water or soft foods (such as yogurt, applesauce, or pudding); it should not be added to hot foods or liquids. The mixture should be stirred well for about 30 seconds and consumed within one hour of mixing.
  • Drug Separation: To ensure that Veltassa does not bind to and reduce the absorption of other oral medications, other drugs must be taken at least 3 hours before or 3 hours after the dose of Veltassa.
  • Missed Dose: If a daily dose is missed, it should be taken as soon as possible on the same day. The dose should not be doubled the next day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Veltassa


1. Evidence for Chronic Hyperkalemia Management

The primary evidence base for Veltassa comes from short-term randomized controlled trials (RCTs) that have explored the use of the medicine in the context of chronic hyperkalemia, a condition characterized by high levels of potassium in the blood. These studies were applied in research contexts involving fluctuating or unstable potassium levels, often in participants with underlying conditions like Chronic Kidney Disease (CKD) or Heart Failure (HF). Studies monitored the key biomarker of serum potassium concentration over defined time intervals.

In these trials, Veltassa was evaluated in studies involving patient groups, including those who were concurrently receiving concomitant RAASi therapy. Findings describe patterns observed in the studies where measurements of serum potassium concentration were recorded as lower during the initial treatment phases. The research also described a pattern of potassium level increase when some participants were switched to a placebo, contrasted with the continued measurement of potassium levels in those who continued the medicine.


2. Evidence in Acute (Non-Life-Threatening) Situations

Veltassa was studied for use in acute settings, meaning in situations where elevated potassium levels were recorded, such as in an emergency department or hospital. However, the evidence for this scenario is limited and primarily involves small pilot studies and the analysis of retrospective data.

These studies focused on episodes where potassium levels became more noticeable. The research describes that the time to observation of changes in potassium levels was protracted, which is why regulatory documents caution against its use in life-threatening hyperkalemia emergencies.


3. Long-Term Studies and Maintenance of Potassium Levels

The research landscape includes open-label extension studies where participants were monitored for periods extending up to 52 weeks (one year). These studies were relevant in trials assessing long-term or episodic potassium patterns. The research observed patterns related to continued potassium level measurement within the target range during the sustained treatment period. However, long-term effects on major clinical events (such as hospital stays or cardiovascular events) are not fully established, as these were generally not the primary outcomes studied.


4. Evidence in Specific Patient Populations

The medicine was evaluated in studies focusing on adults in the context of chronic hyperkalemia, particularly those with CKD and HF. Studies have also monitored a limited number of pediatric patients between the ages of 12 and 17 years. Findings for this age group were observed in some studies, but the sample sizes were modest and data for younger children remain insufficient.


5. Research Gaps and Uncertainty

The pivotal trials relied heavily on a surrogate endpoint—the measurement of potassium in the blood—and not on hard clinical outcomes, such as rates of hospitalization. Therefore, there is limited information for long-term outcomes that reflect a patient’s daily functioning or activity level. The follow-up durations were limited in the main randomized controlled trials, typically spanning less than three months.

Frequently Asked Questions (FAQ)

Common questions about Veltassa (FAQ)


Q: Is it normal to feel a little bloated when first taking Veltassa?

A: It is not uncommon to experience digestive changes when initiating Veltassa treatment. Official product information lists flatulence (gas) and abdominal discomfort as common side effects observed in clinical studies. Gastrointestinal effects are typically described as mild to moderate and may improve as treatment continues.


Q: Can Veltassa cause my calcium or magnesium levels to change?

A: Yes, Veltassa's mechanism as a potassium binder can influence the levels of other minerals. Regulatory documents state that Veltassa commonly causes low magnesium levels (hypomagnesemia). The drug also exchanges for calcium, and these changes often require patient monitoring by a healthcare professional.


Q: If my potassium levels return to normal, do I stop taking Veltassa?

A: Veltassa is generally used for the ongoing management of high potassium, which often requires continued treatment. The duration of therapy is determined by the prescribing physician. Changes to the dose or stopping treatment, even if potassium levels are balanced, must only be done under the direction of a healthcare professional, as stopping the medicine may cause potassium levels to increase.


Q: Are there any signs that Veltassa is not working for me?

A: The primary clinical measure of Veltassa's effectiveness is the serum potassium level, which is monitored through blood tests. If the medicine is not having the desired effect, blood test results would show consistently high potassium. Dose adjustments are based on the results of regular blood tests and must be managed by a healthcare professional.


Q: Is Veltassa's effectiveness reduced if I only mix it with a small amount of water?

A: Official instructions emphasize that the Veltassa powder must be completely mixed with liquid or soft food and the entire mixture consumed within one hour. While regulatory documents do not specify a minimum volume of water, ensuring the powder is fully mixed and the complete dose is consumed is important for the medicine to work as intended.


Q: Is Veltassa used to treat high blood pressure, or just high potassium?

A: Veltassa is indicated solely for the treatment of high potassium levels (hyperkalemia). Its main function is to help lower and maintain potassium balance in the blood, and it is not intended or approved for treating high blood pressure.


Q: How quickly should I expect Veltassa to start lowering my potassium levels?

A: Studies show that the onset of action for Veltassa, meaning the time it takes to begin lowering potassium, occurs approximately 4 to 7 hours after taking a dose. Due to this delayed onset, official labeling cautions that Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia.


Q: Do I need to change my diet while I'm taking Veltassa?

A: Veltassa can be taken with or without food. However, dietary modifications, such as following a low-potassium diet, are often part of a total management plan for hyperkalemia. This should be reviewed with a healthcare professional.


Q: Is it safe to take Veltassa with my daily heartburn medicine?

A: To prevent Veltassa from binding to and potentially reducing the absorption of other oral medicines, including heartburn medicine, they must be administered separately. Regulatory documents require that all other oral medications be taken at least 3 hours before or 3 hours after your dose of Veltassa.


Q: Are there any long-term effects of taking Veltassa every day for years?

A: Clinical trial data from regulatory submissions are limited to exposures of one year or less. While studies have monitored potassium levels over this period, official documents note that the long-term effects on major clinical events (like hospitalization rates) beyond one year are not yet fully established.


Q: Can Veltassa interact with over-the-counter pain relievers like ibuprofen?

A: Veltassa has the potential to bind to many different orally administered medications within the digestive tract. To avoid reducing the absorption of any other oral medicine, including over-the-counter pain relievers such as ibuprofen, they must be taken at least 3 hours before or 3 hours after Veltassa.


Q: Can Veltassa interact with herbal supplements like St. John's Wort?

A: Veltassa is a non-absorbed polymer, so it does not have the same systemic drug interactions as many other medicines. However, because it can bind to and potentially reduce the absorption of almost any oral product, it is necessary to apply the recommended 3-hour separation rule to all oral products, including herbal supplements, to help avoid reduced absorption.


Q: What should I do if the taste of Veltassa makes me feel sick?

A: Nausea is listed as a common side effect in clinical studies. To improve palatability, the powder can be mixed with various liquids (other than hot liquids) or soft foods, such as applesauce, yogurt, or pudding. If nausea is bothersome or persists, a healthcare professional should be consulted.


Q: Does Veltassa affect blood sugar levels for people with diabetes?

A: Veltassa contains sorbitol as part of its composition. Although the impact on blood sugar levels is not generally highlighted, official information states that patients with a rare condition called hereditary fructose intolerance (where sorbitol is poorly tolerated) should not use Veltassa.


Q: Is Veltassa safe to use during pregnancy or while breastfeeding?

A: Studies and regulatory information state that Veltassa is not absorbed into the body (non-systemic). Therefore, use by the mother during pregnancy or while breastfeeding is not expected to result in risk to the fetus or infant.


Q: Is Veltassa used in hospital settings for acute high potassium episodes?

A: No. Due to its delayed onset of action (4–7 hours), Veltassa is specifically not recommended or intended for use as an emergency treatment for life-threatening, acute episodes of hyperkalemia. It is prescribed for the long-term, chronic management of high potassium.

How should Veltassa be stored and disposed of?

How to Store and Dispose of Veltassa

Veltassa (patiromer) powder for oral suspension requires specific temperature control. Unopened sachets should primarily be stored in a refrigerator at 2 C to 8 C (36 F to 46 F) and must not be frozen. [1, 2]

As an alternative, the product may be kept at room temperature (below 25 C) for a maximum duration of six months. The date of removal from the refrigerator should be noted. [1, 3] The medicine must be kept in its original packaging and stored out of the sight and reach of children.

Once the powder is mixed with liquid or soft food, the prepared suspension must be consumed within 1 hour. Any unused or expired Veltassa must be disposed of in accordance with local regulations and should not be discarded via household trash or wastewater. [3, 4]

[1] [2] [3] [4]

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Veltassa found in:

A-Z Index: